| 1 |
24563078 | Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness. | 2014 Mar |
2 |
| 2 |
17227902 | Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. | 2007 Jan |
3 |
| 3 |
17300679 | Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy. | 2007 May-Jun |
4 |
| 4 |
16720854 | Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan. | 2006 May |
1 |
| 5 |
14735180 | Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? | 2004 Jan 26 |
1 |
| 6 |
15364966 | Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? | 2004 Oct 15 |
1 |
| 7 |
10831346 | Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer. | 2000 Jun |
5 |